Pediatric Neuroimaging

Study Description:

We aim to establish the feasibility of recruitment of children aged 9 to 14 years old to obtain high-quality neuroimaging of white matter determinants employing the Bayesian Monte Carlo analysis of multicomponent driven equilibrium single-component observation of T1 and T2 (BMC-mcDESPOT) and constrained neurite orientation dispersion and density imaging (C-NODDI) Magnetic Resonance Imaging (MRI) techniques with a cross-sectional observational pilot study. We additionally aim to establish the feasibility of multidimensional assessment of pubertal status and body composition as they relate to brain white matter. Data from this pilot study would inform the design of our intended future longitudinal investigations gathering reference data descriptive of normative cerebral microstructural changes in a healthy young population.

Objectives:

The primary objective is to demonstrate feasibility of obtaining highquality BMC-mcDESPOT and C-NODDI MRI data from participants between 9 and 14 years old.

The main exploratory objective is to demonstrate the feasibility of completing multidimensional assessments of pubertal status and body composition of participants between 9 and 14 years old to be related to the neuroimaging.

Additional exploratory objectives include investigation of associations of neuroimaging parameters with proteomic and metabolomic biomarkers. We will explore the feasibility of Magnetic Resonance Spectroscopy in this cohort. Biomarkers would include markers for brain cell integrity (mainly oligodendrocytes, but also neurons and other glia) in the soluble phase of plasma and associated with plasma Extracellular Vesicles (EVs), to determine the value of including such parameters in any future longitudinal study.

Endpoints:

The primary endpoint is to obtain high-quality BMC-mcDESPOT and C-NODDI MRI data from up to 30 female and up to 30 male participants between 9 and 14 years old.

The main exploratory endpoint is to complete multidimensional assessments of pubertal status and body composition of up to 30 male and up to 30 female participants between ages 9 and 14 years old.

Additional exploratory endpoints are high-quality MRS images and acquisition of proteomic and metabolomic biomarkers for brain cell integrity in the soluble phase of plasma and plasma EVs.

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Male or female, 9 to 14 years of age.
• In good general health
• Ability of parent/guardian to understand and the willingness to sign a written informed consent document.
• Ability of participant to participate in the assent process and willingness to sign a written informed assent document.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

• Any known brain abnormalities (e.g. tumor, periventricular leukomalacia, microcephaly) or history of medical conditions known to affect cerebral micro or macro-structural integrity (e.g., epilepsy, history of stroke, head injury with a loss of consciousness of one hour or more).
• History neurodevelopmental delay or disorder, learning disability, intellectual disability (formerly referred to as mental retardation), autism spectrum disorders, and attention deficit/hyperactivity disorder (ADHD)), as evaluated history, physical and by the SDQ, and if indicated, the KSADS
• History of psychiatric disorder as evaluated by history and the SDQ, and if indicated, the KSADS.
• History of prematurity (< 32 weeks gestational age).
• History of endocrine abnormalities, including diagnosed disorders of thyroid, growth, and precocious or delayed puberty
• History of major medical conditions or chronic medical conditions. Examples include neurological disorders, medical or genetic conditions with associated neurological manifestations, malnutrition, conditions raising risk of micronutrient or macronutrient deficiencies (e.g. inflammatory bowel disease), untreated chronic anemia, cardiovascular disease, significant lung disease (e.g. bronchiectasis), significant liver disease, significant kidney disease, significant autoimmune condition, and chronic infections (e.g. HIV, hepatitis B).
• Pregnancy.
• Not eligible to have an MRI as per the MRI eligibility form and the safety standards of the NIA 3T MRI center.
• Presence of hardware (e.g. orthodontic braces) that may interfere with MRI data quality.
• Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.